AYTU
AYTU BIOPHARMA, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.90
−4.04%Year over year
Reported trailing growth
- Revenue
- -13.3%
- EBITDA
- -75.6%
- EBIT
- -6.2%
- EPS
- +33.1%
- Free cash flow
- +250.2%
- Operating cash flow
- +269.4%
Forward estimates
Based on analyst estimates
- Revenue
- +27.0%
- EBITDA
- +102.4%
- EPS
- +73.3%
Three-year CAGR
- Revenue
- -18.8%
- EBITDA
- +6.0%
- EBIT
- -6.2%
- Net income
- -5.1%
- EPS
- +46.3%
- Free cash flow
- +163.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026